BVF PARTNERS L P/IL Insider Trading $FPRX FIVE PRIME THERAPEUTICS, INC.

FREE EMAIL WATCHDOG

Get free email notifications about insider trading for BVF PARTNERS L P/IL.

  • Your email is safe with us.
  • The service is free and you can unsubscribe at any time.

General | Insider Transactions | Monthly Overview

Get the latest insider transactions of BVF PARTNERS L P/IL. BVF PARTNERS L P/IL is in Capstone Therapeutics Corp. ($CAPS) and 10% Owner in CTI BIOPHARMA CORP ($CTIC) and Director in CTI BIOPHARMA CORP ($CTIC) and 10% Owner in XOMA Corp ($XOMA) and Director in XOMA Corp ($XOMA) and 10% Owner in ARQULE INC ($ARQL) and 10% Owner in INFINITY PHARMACEUTICALS, INC. ($INFI) and in FIVE PRIME THERAPEUTICS, INC. ($FPRX) and 10% Owner in FIVE PRIME THERAPEUTICS, INC. ($FPRX) and in CYTOKINETICS INC ($CYTK) and 10% Owner in CYTOKINETICS INC ($CYTK) and 10% Owner in GLYCOMIMETICS INC ($GLYC) and 10% Owner in CONCERT PHARMACEUTICALS, INC. ($CNCE) and 10% Owner in Syndax Pharmaceuticals Inc ($SNDX) and in Eledon Pharmaceuticals, Inc. ($NVUS) and in ChemoCentryx, Inc. ($CCXI) and 10% Owner in ChemoCentryx, Inc. ($CCXI) and 10% Owner in IMMUNE DESIGN CORP. ($IMDZ) and 10% Owner in Calithera Biosciences, Inc. ($CALA) and 10% Owner in Principia Biopharma Inc. ($PRNB) and 10% Owner in PIERIS PHARMACEUTICALS, INC. ($PIRS) and 10% Owner in Xenon Pharmaceuticals Inc. ($XENE) and 10% Owner in Nivalis Therapeutics, Inc. ($NVLS) and 10% Owner in Merus N.V. ($MRUS) and in IDEAYA Biosciences, Inc. ($IDYA) and 10% Owner in IDEAYA Biosciences, Inc. ($IDYA) and Director in Rain Therapeutics Inc. ($RAIN) and Director in Olema Pharmaceuticals, Inc. ($OLMA) and Director in Kymera Therapeutics, Inc. ($KYMR).

Over the past year BVF PARTNERS L P/IL has been an insider in 11 companies. The total value of shares held by BVF PARTNERS L P/IL in these companies amounts to $226,487,611.

BVF PARTNERS L P/IL 10% Owner
ALPINE IMMUNE SCIENCES, INC.
10% Owner
ARQULE INC
10% Owner
Calithera Biosciences, Inc.
Capstone Therapeutics Corp.
ChemoCentryx, Inc.
10% Owner
CONCERT PHARMACEUTICALS, INC.
Director, 10% Owner
CTI BIOPHARMA CORP
CYTOKINETICS INC
Eledon Pharmaceuticals, Inc.
FIVE PRIME THERAPEUTICS, INC.
10% Owner
GLYCOMIMETICS INC
IDEAYA Biosciences, Inc.
10% Owner
IMMUNE DESIGN CORP.
10% Owner
INFINITY PHARMACEUTICALS, INC.
Director
Kymera Therapeutics, Inc.
10% Owner
Merus N.V.
Director
Olema Pharmaceuticals, Inc.
10% Owner
PIERIS PHARMACEUTICALS, INC.
10% Owner
Principia Biopharma Inc.
Director
Rain Therapeutics Inc.
10% Owner
Syndax Pharmaceuticals Inc
10% Owner
Xenon Pharmaceuticals Inc.
Director, 10% Owner
XOMA Corp
$ 226487611 The total value of shares held by BVF PARTNERS L P/IL
Insider Rank

BVF PARTNERS L P/IL ranks 209 out of 350,000 insiders. Go to Insider Ranking to see more.

BVF PARTNERS L P/IL in FIVE PRIME THERAPEUTICS, INC.

Trading Symbol: FPRX
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of BVF PARTNERS L P/IL:
Holdings: 670,695 shares
Current Value: $30,436,139
Latest Transaction: Nov 13 2020
$FPRX Market Capitalization: $1.23B
$FPRX Previous Close: $45.38

Last 4 weeks trend: STRONG SELL
Last 3 months trend: STRONG SELL

Last 3 Months Overview:
Buy: 47x
Sell: 3x
Shares Bought: 4,177,168
Shares Sold: 7,393,340
Share Difference: -3,216,172
Value Difference: +$132,997,133

Latest Insider Trading Transactions of BVF PARTNERS L P/IL in FIVE PRIME THERAPEUTICS, INC.

1 Week2 Weeks1 Month3 Months6 Months1 Year2 Years
No. of Purchases00000019
Value of Purchases ($)00000013,250,904
No. of Sales0000033
Value of Sales ($)00000149,247,136149,247,136

Sentiment: All, ALPN, ARQL, CALA, CAPS, CCXI, CNCE, CTIC, CYTK, ELDN, FPRX, GLYC, IDYA, IMDZ, INFI, KYMR, MRUS, OLMA, PIRS, PRNB, RAIN, SNDX, XENE, XOMA

Page:   1

DateTickerCompanyOwnerRelationship Transaction Code Cost ($) Shares Transaction Value ($) Total Shares % Holdings
Nov 13 2020FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/ILSellS20.19502,64910,146,82581,263583.9 K to 81.3 K (-86.08 %)
Nov 13 2020FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/ILSellS20.192,949,47759,540,207485,5133.4 M to 485.5 K (-85.87 %)
Nov 13 2020FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/ILSellS20.193,941,21479,560,105670,6954.6 M to 670.7 K (-85.46 %)
Oct 08 2020FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP5.0425,107126,414566,223541.1 K to 566.2 K (+4.64 %)
Oct 08 2020FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP5.04162,352817,4423,281,1513.1 M to 3.3 M (+5.21 %)
Oct 08 2020FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP5.04157,782794,4324,336,8754.2 M to 4.3 M (+3.78 %)
Sep 24 2020FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.8032122541,116541.1 K to 541.1 K (+0.01 %)
May 18 2020FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP4.104,47618,352541,084536.6 K to 541.1 K (+0.83 %)
May 18 2020FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP4.1039,810163,2213,118,7993.1 M to 3.1 M (+1.29 %)
May 18 2020FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP4.10249,3011,022,1344,179,0933.9 M to 4.2 M (+6.34 %)
Dec 26 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP4.0532,606132,054536,608504 K to 536.6 K (+6.47 %)
Dec 26 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP4.05201,096814,4393,078,9892.9 M to 3.1 M (+6.99 %)
Dec 26 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP4.05281,3181,139,3383,929,7923.6 M to 3.9 M (+7.71 %)
Dec 11 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP4.022,3979,630504,002501.6 K to 504 K (+0.48 %)
Dec 11 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP4.0218,72975,2442,877,8932.9 M to 2.9 M (+0.66 %)
Dec 11 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP4.02113,874457,4893,648,4743.5 M to 3.6 M (+3.22 %)
Nov 26 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.4081,857278,322501,605419.7 K to 501.6 K (+19.50 %)
Nov 26 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.40462,0561,571,0372,859,1642.4 M to 2.9 M (+19.28 %)
Nov 26 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.40576,0971,958,7873,534,6003 M to 3.5 M (+19.47 %)
Nov 07 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP4.0070,921283,684419,748348.8 K to 419.7 K (+20.33 %)
Nov 07 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP4.00400,4701,601,8802,397,1082 M to 2.4 M (+20.06 %)
Nov 07 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP4.00496,7211,986,8842,958,5032.5 M to 3 M (+20.18 %)
Oct 31 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.855041,940348,827348.3 K to 348.8 K (+0.14 %)
Oct 31 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.852,91311,2141,996,6382 M to 2 M (+0.15 %)
Oct 31 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.853,41613,1502,461,7822.5 M to 2.5 M (+0.14 %)
Oct 31 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.891,4565,667348,323346.9 K to 348.3 K (+0.42 %)
Oct 31 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.898,23632,0551,993,7252 M to 2 M (+0.41 %)
Oct 31 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.8910,38940,4352,458,3662.4 M to 2.5 M (+0.42 %)
Oct 31 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.90240935346,867346.6 K to 346.9 K (+0.07 %)
Oct 31 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.901,1334,4151,985,4892 M to 2 M (+0.06 %)
Oct 31 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.901,0274,0022,447,9772.4 M to 2.4 M (+0.04 %)
Oct 25 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.752,1558,075346,627344.5 K to 346.6 K (+0.63 %)
Oct 25 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.7512,89948,3361,984,3562 M to 2 M (+0.65 %)
Oct 25 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.7515,72858,9382,446,9502.4 M to 2.4 M (+0.65 %)
Oct 25 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.741,6296,100344,472342.8 K to 344.5 K (+0.48 %)
Oct 25 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.7457,723216,1551,971,4571.9 M to 2 M (+3.02 %)
Oct 25 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.7476,036284,7322,431,2222.4 M to 2.4 M (+3.23 %)
Oct 25 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.753,20011,9862,355,1862.4 M to 2.4 M (+0.14 %)
Oct 08 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.684,68917,270342,843338.2 K to 342.8 K (+1.39 %)
Oct 08 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.6824,71691,0291,913,7341.9 M to 1.9 M (+1.31 %)
Oct 08 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.6831,007114,1992,351,9862.3 M to 2.4 M (+1.34 %)
Oct 08 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.7524,42591,594338,154313.7 K to 338.2 K (+7.79 %)
Oct 08 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.7514,24253,382313,729299.5 K to 313.7 K (+4.76 %)
Oct 08 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.75138,609519,7841,889,0181.8 M to 1.9 M (+7.92 %)
Oct 08 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.7580,821302,9331,750,4091.7 M to 1.8 M (+4.84 %)
Oct 08 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.75168,640632,4002,320,9792.2 M to 2.3 M (+7.84 %)
Oct 08 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.7598,333368,5722,152,3392.1 M to 2.2 M (+4.79 %)
Oct 08 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.749913,704299,487298.5 K to 299.5 K (+0.33 %)
Oct 08 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.747,31427,3361,669,5881.7 M to 1.7 M (+0.44 %)
Oct 08 2019FPRXFIVE PRIME THERAPE ...BVF PARTNERS L P/IL10% OwnerBuyP3.747,69528,7602,054,0062 M to 2.1 M (+0.38 %)

Page:   1